The Food and Drug Administration is weighing whether to approve the use of MDMA, also known as Ecstasy, for treatment of post-traumatic stress disorder. An independent advisory panel of experts will review studies on Tuesday and is expected to vote on whether the treatment would be effective and whether its benefits outweigh the risks. The…
The Food and Drug Administration on Friday raised concerns about the health effects of MDMA as a treatment for post-traumatic stress disorder, citing flaws in a company’s studies that could pose major obstacles to approval of a treatment anticipated to help people struggling with the condition. The agency said that bias had seeped into the…
About two weeks after Marcell Leon Viragh moved into the Park Santa Monica, a Los Angeles building where residents can sweat in a Himalayan salt sauna or gaze at the Pacific Ocean from the expansive roof deck, he took the elevator down to the spa, where a registered nurse slid a needle into a vein…
On Wednesday, Kendric Cromer, a 12-year-old boy from a suburb of Washington, became the first person in the world with sickle cell disease to begin a commercially approved gene therapy that may cure the condition. For the estimated 20,000 people with sickle cell in the United States who qualify for the treatment, the start of…
The drug company Atai Life Sciences is spending millions to research the compound, and congressional lawmakers from both parties have been pushing the government to promote ibogaine research for substance abuse, post-traumatic stress disorder and other mental health problems. For Dr. Deborah Mash, a professor of neurology at the University of Miami who began studying…
The drug company Atai Life Sciences is spending millions to research the compound, and congressional lawmakers from both parties have been pushing the government to promote ibogaine research for substance abuse, post-traumatic stress disorder and other mental health problems. For Dr. Deborah Mash, a professor of neurology at the University of Miami who began studying…
